Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Current Assets (2020 - 2025)

Historic Current Assets for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $280.9 million.

  • Bioventus' Current Assets fell 595.5% to $280.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $280.9 million, marking a year-over-year decrease of 595.5%. This contributed to the annual value of $275.6 million for FY2024, which is 283.99% up from last year.
  • As of Q3 2025, Bioventus' Current Assets stood at $280.9 million, which was down 595.5% from $275.2 million recorded in Q2 2025.
  • Bioventus' Current Assets' 5-year high stood at $308.9 million during Q2 2024, with a 5-year trough of $245.4 million in Q2 2022.
  • In the last 5 years, Bioventus' Current Assets had a median value of $271.1 million in 2022 and averaged $272.5 million.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 2578.25% in 2023, then tumbled by 1385.36% in 2024.
  • Quarter analysis of 5 years shows Bioventus' Current Assets stood at $263.1 million in 2021, then increased by 3.6% to $272.6 million in 2022, then dropped by 1.68% to $268.0 million in 2023, then rose by 2.84% to $275.6 million in 2024, then increased by 1.92% to $280.9 million in 2025.
  • Its Current Assets stands at $280.9 million for Q3 2025, versus $275.2 million for Q2 2025 and $249.4 million for Q1 2025.